You are here

  • Home
  • Archive
  • Volume 77, Issue Suppl 2
  • FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis

Article metrics

Article menu

Download PDFPDF

FRIDAY, 15 JUNE 2018
SLE, Sjögren’s and APS – treatment
FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis
Free

 

Online download statistics by month:

Online download statistics by month: June 2018 to March 2024

AbstractFullPdf
Jun 201886011
Jul 201882031
Aug 201866012
Sep 2018184018
Oct 2018154018
Nov 201896016
Dec 201874012
Jan 2019169019
Feb 2019106014
Mar 2019132027
Apr 2019163020
May 2019114016
Jun 2019142016
Jul 2019130018
Aug 2019134022
Sep 2019168024
Oct 2019200025
Nov 2019139035
Dec 2019165016
Jan 2020121014
Feb 2020108011
Mar 202074011
Apr 2020100018
May 202070020
Jun 20207108
Jul 202063013
Aug 202087018
Sep 202074017
Oct 202062011
Nov 20202304
Dec 20202805
Jan 202157015
Feb 202166015
Mar 202148014
Apr 20213104
May 20211009
Jun 2021102
Jul 20217010
Aug 2021606
Sep 2021103
Oct 202121018
Nov 202138020
Dec 20211202
Jan 20221902
Feb 20221505
Mar 20221402
Apr 20221907
May 202213011
Jun 20221304
Jul 20221904
Aug 20221205
Sep 202218012
Oct 20221303
Nov 202232014
Dec 20221207
Jan 20231604
Feb 20231202
Mar 20231204
Apr 2023202
May 20231505
Jun 20232205
Jul 20232307
Aug 20235909
Sep 202312903
Oct 202329106
Nov 202349201
Dec 20232504
Jan 20242805
Feb 20243206
Mar 202418059
Total50580836